CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment
Barbara Buldini, Elena Varotto, Margarita Maurer‐Granofszky, Giuseppe Gaipa, Angela Schumich, Monika Brüggemann, Ester Mejstříková, Giovanni Cazzaniga, Ondřej Hrušák, Monika Szczepanowski, Pamela Scarparo, Martin Zimmermann, Sabine Strehl, Dagmar Schinnerl, Markéta Žaliová, Leonid Karawajew, Jean‐Pierre Bourquin, Tamar Feuerstein, Gunnar Cario, Julia Alten, Anja Möricke, Alessandra Biffi, Rosanna Parasole, Franca Fagioli, Maria Grazia Valsecchi, Andrea Biondi, Franco Locatelli, Andishe Attarbaschi, Martin Schrappe, Valentino Conter, Giuseppe Basso, Michael Dworzak
Abstract
ABSTRACT: In the effort to improve immunophenotyping and minimal residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster (iBFM) Flow Network introduced the myelomonocytic marker CD371 for a large prospective characterization with a long follow-up. In the present study, we aimed to investigate the clinical and biological features of CD371-positive (CD371pos) pediatric B-cell precursor ALL (BCP-ALL). From June 2014 to February 2017, 1812 pediatric patients with newly diagnosed BCP-ALLs enrolled in trial AIEOP-BFM ALL 2009 were evaluated as part of either a screening (n = 843, Italian centers) or validation cohort (n = 969, other iBFM centers). Laboratory assessment at diagnosis consisted of morphological, immunophenotypic, and genetic analysis. Response assessment relied on morphology, multiparametric flow cytometry (MFC), and polymerase chain reaction (PCR)-MRD. At diagnosis, 160 of 1812 (8.8%) BCP-ALLs were CD371pos. This correlated with older age, lower ETV6::RUNX1 frequency, immunophenotypic immaturity (all P < .001), and strong expression of CD34 and of CD45 (P < .05). During induction therapy, CD371pos BCP-ALLs showed a transient myelomonocytic switch (mm-SW: up to 65.4% of samples at day 15) and an inferior response to chemotherapy (slow early response, P < .001). However, the 5-year event-free survival was 88.3%. Among 420 patients from the validation cohort, 27 of 28 (96.4%) cases positive for DUX4-fusions were CD371pos. In conclusion, in the largest pediatric cohort, CD371 is the most sensitive marker of transient mm-SW, whose recognition is essential for proper MFC MRD assessment. CD371pos is associated to poor early treatment response, although a good outcome can be reached after MRD-based ALL-related therapies.